AZD3293(Lanabecestat)

Modify Date: 2024-01-09 10:31:28

AZD3293(Lanabecestat) Structure
AZD3293(Lanabecestat) structure
Common Name AZD3293(Lanabecestat)
CAS Number 1383982-64-6 Molecular Weight 412.527
Density 1.2±0.1 g/cm3 Boiling Point 621.9±65.0 °C at 760 mmHg
Molecular Formula C26H28N4O Melting Point N/A
MSDS N/A Flash Point 329.9±34.3 °C

 Use of AZD3293(Lanabecestat)


Lanabecestat (AZD3293) is a potent, highly permeable, orally active and blood-brain barrier penetrating BACE1 inhibitor with a Ki of 0.4 nM.

 Names

Name Lanabecestat
Synonym More Synonyms

 AZD3293(Lanabecestat) Biological Activity

Description Lanabecestat (AZD3293) is a potent, highly permeable, orally active and blood-brain barrier penetrating BACE1 inhibitor with a Ki of 0.4 nM.
Related Catalog
Target

Ki: 0.4 nM (BACE1)[1]

In Vitro Lanabecestat acts as a full inhibitor of BACE1 in vitro, with a competitive and reversible mechanism of action towards the hBACE1 active site. Lanabecestat displays a very high target affinity and a markedly slow target off-rate. The off-rate of lanabecestat has an estimated t1/2 of approximately 9 h. Lanabecestat displays pM potency in primary neuron cultures from mice and guinea pigs and in SH-SY5Y cells over-expressing AβPP (IC50=610 pM, 310 pM, and 80 pM, respectively). The in vitro plasma protein binding of lanabecestat is determined by equilibrium dialysis using mouse, rat, guinea pig, dog, and human plasma. The compound is stable in the plasma of these species for at least the duration of the in vitro incubation period. The unbound fractions are 1.3% to 1.8% for mice, 4.2% to 5.9% for rats, 8.3% to 10.3% for guinea pigs, 9.4% to 10.3% for dogs, and 7.7% to 9.4% for human plasma. The mean blood:plasma ratio of 0.7 in human blood indicates no significant association with red blood cells. The free fraction in the brain tissue binding assay is 4.5%[1].
In Vivo In mice, guinea pigs, and dogs, lanabecestat displays significant dose- and time-dependent reductions in plasma, cerebrospinal fluid, and brain concentrations of Aβ40, Aβ42, and sAβPPβ[1].
Cell Assay Cells are incubated with different lanabecestat concentrations for 5 to 16 h, and the release of sAβPPβ, Aβ1-40, Aβ1-42, or sAβPPα into the medium is analyzed using kits. Cytotoxic effect of lanabecestat is evaluated in the cell plates using cell proliferation/cytotoxicity kit[1].
Animal Admin Female 7- to 14-week-old C57BL/6 mice (n=6 per treatment group and timepoint) receive vehicle or lanabecestat solution at 50, 100, or 200 μmol/kg (20, 41, or 82 mg/kg) as a single dose via oral gavage. Mice and guinea pigs are anesthetized 1.5, 2, 3, 4, 6, 8, 16, 24, or 48 h after the (last) administration of vehicle or drug and are then kept under isoflurane anesthesia. Cerebrospinal fluid (CSF) is aspirated from the cisterna magna, and plasma is isolated from blood collected by cardiac puncture into EDTA tubes. The animals are then sacrificed by decapitation, and the brains are dissected into hemispheres[1].
References

[1]. Eketj?ll S, et al. AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics. J Alzheimers Dis. 2016;50(4):1109-23.

 Chemical & Physical Properties

Density 1.2±0.1 g/cm3
Boiling Point 621.9±65.0 °C at 760 mmHg
Molecular Formula C26H28N4O
Molecular Weight 412.527
Flash Point 329.9±34.3 °C
Exact Mass 412.226318
LogP 3.02
Vapour Pressure 0.0±1.8 mmHg at 25°C
Index of Refraction 1.656
Storage condition -20℃

 Synonyms

LY3314814
(1r,1'R,4R)-4-Methoxy-5''-methyl-6'-[5-(1-propyn-1-yl)-3-pyridinyl]-3'H-dispiro[cyclohexane-1,2'-indene-1',2''-imidazol]-4''-amine
AZD3293
UNII:X8SPJ492VF
Dispiro[cyclohexane-1,2'-[1H]indene-1'(3'H),2''-[2H]imidazol]-4''-amine, 4-methoxy-5''-methyl-6'-[5-(1-propyn-1-yl)-3-pyridinyl]-, (1'R)-
Lanabecestat
Top Suppliers:I want be here


Get all suppliers and price by the below link:

AZD3293(Lanabecestat) suppliers


Price: $227/10mM*1mLinDMSO

Reference only. check more AZD3293(Lanabecestat) price